Translating novel science into life-saving medicines
Targeting those patients most
likely to benefit
Developing precision medicines for cancer
Skip to content
Board of Directors
Tipifarnib – HRAS
Tipifarnib – PTCL
Tipifarnib – MDS
ERK Inhibitor Program
Menin-MLL Inhibitor Program
Events & Presentations
Kura Oncology Reports Second Quarter 2016 Financial Results»
Kura Oncology to Report Second Quarter 2016 Financial Results»
Kura's pipeline consists of small molecule drug candidates designed to inhibit mutated or abnormally functioning signaling pathways that drive cancer growth.
Kura is conducting clinical trials intended to identify and enroll patients most likely to respond to treatment.